PD-L1 Gene Mutation
10 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV (NCT05330143) | Ascletis Pharmaceuticals Co., Ltd. | 2022-06-28 |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC (NCT04925986) | Sarah Goldberg | 2022-02-10 |
| Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC (NCT05233696) | University of Colorado, Denver | 2022-01-04 |
| Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients (NCT04470674) | Shirish M Gadgeel | 2021-04-06 |
| Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC (NCT04754815) | Shirish Gadgeel | 2021-04-01 |
| Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (NCT04716946) | Memorial Sloan Kettering Cancer Center | 2021-01-27 |
| Atezolizumab Plus CArboplatin Plus Nab-paclitaxel (NCT05266937) | Consorzio Oncotech | 2020-07-03 |
Track PD-L1 Gene Mutation automatically
Every clearance here is in the API, with alerts when new ones post.